Guangdong Metabolic Diseases Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmac
2 developments in the corpus
Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A single-centre, uncontrolled observational study with modest sample size (n=56 MDD patients) showing biomarker changes in response to treatment and diagnostic discrimination, but lacking a randomized comparator arm and requiring external validation before clinical deployment.
Preclinical mechanistic study in animal models and cell cultures demonstrating pathway involvement; lacks clinical efficacy data, human trials, or quantified effect sizes to support clinical translation.